Creative Planning Buys 2,486 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Creative Planning increased its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 13.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,348 shares of the company’s stock after buying an additional 2,486 shares during the quarter. Creative Planning’s holdings in Health Catalyst were worth $174,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of HCAT. Susquehanna Fundamental Investments LLC purchased a new stake in Health Catalyst in the first quarter worth $1,079,000. Inspire Investing LLC purchased a new position in shares of Health Catalyst during the first quarter valued at $355,000. Gruss & Co. LLC purchased a new position in shares of Health Catalyst during the first quarter valued at $188,000. Acadian Asset Management LLC increased its stake in shares of Health Catalyst by 38.3% during the first quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after buying an additional 200,494 shares during the period. Finally, EntryPoint Capital LLC purchased a new position in shares of Health Catalyst during the first quarter valued at $98,000. 85.00% of the stock is currently owned by institutional investors.

Insider Activity at Health Catalyst

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the sale, the chief operating officer now owns 134,899 shares of the company’s stock, valued at approximately $1,036,024.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,396 shares of company stock valued at $266,280 in the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Health Catalyst Stock Performance

HCAT opened at $8.32 on Tuesday. Health Catalyst, Inc. has a one year low of $5.42 and a one year high of $11.41. The company has a market cap of $503.11 million, a P/E ratio of -6.13 and a beta of 1.32. The business’s 50-day simple moving average is $8.07 and its 200-day simple moving average is $7.16.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.49%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period last year, the company earned ($0.22) earnings per share. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. As a group, analysts predict that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Evercore ISI raised their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Royal Bank of Canada raised their price objective on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Stephens lowered their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. raised their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Health Catalyst has a consensus rating of “Moderate Buy” and an average price target of $11.64.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.